Asset profile

NRX-101

Small molecule

Phase 3underway

Evidence outlook · registrational

Major Depressive Disorder: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12-31.

How the evidence outlook works ↗

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (1)
December 2027 (1)
Phase 2/3Major Depressive DisorderNot yet recruiting
Est. primary completion 2027-12-31 · NCT07227103 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.